Jim Cramer's top 10 things to watch in the stock market Wednesday

Stocks are rallying on hopes the Iran conflict may be nearing an end, with oil plunging and futures higher; travel, aerospace and other risk assets are benefiting, while the S&P 500 and Nasdaq remain at record highs. The article also highlights several strong company-specific catalysts: Corning/Nvidia announced a major optical deal, AMD issued better-than-expected guidance, Novo Nordisk lifted guidance, CVS beat and raised outlook, and Disney posted a revenue beat with $8 billion in buybacks. Overall, the tone is risk-on with multiple large-cap winners tied to AI, healthcare, and consumer recovery.

Analysis

The market is rewarding the same macro setup from two different angles: falling geopolitical risk is taking a pressure release valve off transport, aerospace, and consumer discretionary, while the AI capex cycle is broadening from chips into the physical bottlenecks that actually constrain deployment. The key second-order effect is that this is no longer a pure software/microchip trade; power, optics, backup generation, and industrial automation are becoming the tollbooths on AI scaling, which helps explain why the biggest upside is accruing to the least-obvious enablers rather than only the hyperscalers.

The most interesting relative-value signal is that supply-chain scarcity is migrating from semis to infrastructure inputs. Optical interconnects, data-center backup power, and factory automation should keep seeing backlog extension for multiple quarters even if headline AI enthusiasm cools, because customers are trying to de-risk deployment timing rather than optimize price. That argues for owning the picks-and-shovels names with pricing power and underappreciated domestic capacity, while being more selective on the larger cap names where expectations are already elevated.

Healthcare is acting like a hidden high-quality growth bucket: obesity-drug momentum and insurer improvement are both moving from story to earnings revisions. The market may still be underestimating how quickly GLP-1 penetration can reshape pharmacy, payer, and consumer behavior over the next 12 months. On the other hand, travel and aerospace are the most tactically exposed to any reversal in war de-escalation headlines; those moves can unwind fast if diplomacy slips or if oil snaps back on any supply shock.

The contrarian read is that the strongest near-term upside may actually be in names with the least narrative excitement but the most visible order books. If investors chase the obvious AI leaders after the open, the higher quality entry may be in industrial enablers and domestic manufacturing beneficiaries, especially where the capex cycle is being amplified by policy and onshoring rather than just sentiment. The biggest risk is a broad relief rally becoming too crowded; in that case, the market will likely rotate from beta-sensitive winners into more durable compounders within days to weeks.

Key Decisions for Investors

• Buy GLW on pullbacks over the next 1-2 sessions; risk/reward remains favorable because the optical capacity buildout is a multi-quarter demand bottleneck story, not a one-day headline trade.
• Stay long AMD versus NVDA for the next 1-3 months as a relative-value trade; AMD has more room for estimate revisions from AI-server CPU demand, while NVDA is more exposed to perfection risk after a large move.
• Initiate a long ROK / short cyclical industrial basket on a 3-6 month horizon; automation and onshoring demand should hold even if macro growth moderates, with lower downside than higher-beta manufacturing names.
• Buy CMI on weakness and consider call spreads for 6-9 month exposure; data-center generator demand is a structural backlog driver that should persist even if the AI trade rotates.
• For tactical event risk, use call spreads in BA and GE only, not outright longs, for the next 2-4 weeks; they benefit if de-escalation holds, but the move is headline-sensitive and can reverse sharply.